Background
Introduction
In the absence of an efficient diagnostic modality for Tuberculosis [TB] , the search for a tool that can overcome the dilemmas of the available diagnostic tests continues. In the wake of continued reports of high mortality and morbidity due to TB, WHO approved GeneXpert MTB/ RIF [Cepheid, Sunnyvale, CA, USA] in 2011 and recommended it for rapid implementation [1] . Several studies have since published evaluation and validation reports [2, 3, 4] .
TB control programs and treatment protocols primarily target active TB disease. Hence early diagnosis and institution of early treatment is not directed only towards the individual but also serves to prevent transmission in the community, especially important for drug resistant TB. Smear with its poor sensitivity and culture with the prolonged turnaround time fail to cater to this important need for early diagnosis. Gandhi et al reported that in a cohort of HIV-MDR-TB patients, 50% died before the culture/drug susceptibility testing [DST] report was generated [5] . It is towards this goal that rapid molecular diagnostics offering great promise have been developed [6] .
The GeneXpert MTB/RIF System offers an efficient and rapid, near patient technology, capable of simultaneously detecting M. tuberculosis [MTB] and resistance to Rif. The handsfree sample processing and DNA extraction platform coupled with a Real-time PCR gives a Limit of Detection [LOD] of 4.5 genomes per reaction, and a clinical LOD of 131cfu/ml [2] . The reported sensitivity ranges between 72.5-98.2% [smear negative and smear positive samples respectively] with a specificity of 98.2% [3] . The system is easy to use, bio-safe and ensures absence of any sample cross contamination.
The limitations of the test include detection of drug resistance to Rif alone [hence its inability to identify XDR-TB from MDR-TB, [Rif being a surrogate marker for MDR]] and identification of drug resistance from a mixed population [the rpoB allele responsible for RIF resistance should be present in at least 65% of DNA present in the sample] [4] . Further limitations have been reported with respect to reporting of Leu533Pro mutations unless 100% of DNA population in the sample has the mutation [4, 7] an error that is reported to be overcome by using G4 cartridges [7] .
The estimate of primary MDR-TB [MDR in new TB cases] in India is 2.2% while MDR-TB in re-treatment TB cases is 15% [8] . However studies from tertiary care centers report higher MDR-TB possibly due to referral bias and difficulty in diagnosing an indolent disease [9] . TB in EP sites is also a diagnosis more often confirmed in tertiary care centers due to complex clinical presentation and need for invasively collected samples. Currently the Revised National TB Control Program [RNTCP] endorses GeneXpert MTB/RIF for diagnosis of MDR TB among MDRTB suspects and for diagnosis of TB among certain vulnerable populations [HIV infected TB suspects and pediatric TB suspects] [10, 11] .
A few studies have raised concerns regarding the assay performance in patient care settings with respect to sensitivity, specificity, indeterminate results, inefficient detection of Rif monoresistance and certain disputed mutations. The aim of the present study was to assess the performance of GeneXpert MTB/RIF for the diagnosis of pulmonary and extrapulmonary TB, and for the detection of Rif resistance in a tertiary level patient care setting
Material and Methods
Design, setting and study population A prospective study was conducted at the Tuberculosis Division, Department of Microbiology, All India Institute of Medical Sciences New Delhi, India a multi-specialty tertiary care, teaching and referral hospital, with 2500 bed capacity. A number of patients with chronic extra-pulmonary presentations report to different specialties, as they remain undiagnosed in the peripheral centers. From March 2012 to June 2014, two thousand forty two patients presenting with symptoms potentially due to pulmonary or extra-pulmonary tuberculosis were screened and enrolled if they fulfilled the inclusion criteria. Patients with the following inclusion criteria were included in the study: Patients of either sex aged between 15 to 60 yrs, free from any underlying disease or prior infection of lung, anti-tuberculosis treatment [ATT] naïve, willing and able to give valid informed written consent. Patients with the following exclusion criteria were excluded from the study: patient unwilling and unable to give valid informed written consent, patients with known clinical diagnosis other than the disease in question, patients already on ATT, and patients with HIV infection.
One thousand one hundred forty five patients with high clinical suspicion of TB but not initiated on ATT at the time of enrollment, were enrolled in the study [Fig 1] . All samples were collected using standard protocol [12] . CSF was collected from patients presenting with fever, irritability, restlessness, neck stiffness and rigidity, headache persistent for 2-3 weeks, vomiting, seizures, and focal neurological deficit. Patients presenting with sub-acute intestinal obstruction, abdominal pain, alternating diarrhea and constipation were subjected to endoscopic/colonoscopic examination and biopsy from any abnormal/ulcerated region was collected for diagnostic workup. Patients presenting with enlargement of lymph nodes, neck swelling / draining sinus were subjected to "Fine needle aspiration" of the lymph nodes which was sent to the laboratory for the diagnostic tests. Patients presenting with shortness of breath, chest pain, dyspnea with fluid level and no other chest findings on the X-ray, were subjected to a pleural tap. The pleural fluid was further processed for smear, culture, and GeneXpert. Only one sample was collected where invasive techniques were used, while sputum samples were collected on two occasions from patients presenting with chronic cough, fever, chest pain, symptoms suggestive of pulmonary TB. Samples were divided into 3 aliquots namely for Smear microscopy and culture [LJ and MGIT 960 system], GeneXpert Assay and storage in -80 0 C.
Samples
The invasively collected specimens were processed singly. The sputum specimens were processed using NALC-NaOH method [N-acetyl-L-cysteine-NaOH-sodium citrate method] for making smears, and pooled for culture and GeneXpert tests [13] . Sterile body fluids were centrifuged and the pellet was used as inoculum.
AFB smears
The processed specimens were used for making smears for all samples. All the smears were stained by the Ziehl Neelsen method and examined with a light microscope [14] .
MGIT 960
Samples were inoculated into MGIT 960 non-radiometric automated isolation system [Becton Dickinson, Sparks, MD, USA]; the MGIT tube containing 7 ml of 7H9 medium, supplemented with 0. 
GeneXpert
The Xpert assay was performed according to manufacturer's instructions [Cepheid, Sunnyvale, CA] using latest version of G4 cartridges. [3, 4, 16] . In the Xpert assay, sample reagent was added at a 2:1 ratio to clinical specimens and it was incubated for 15 min at room temperature with intermittent shaking. Following which, 3 ml of the inactivated material was transferred to the cartridge. The cartridges were inserted into the test device and the results were generated after 90 min. [16] Repeat GeneXpert MTB/RIF tests were run for results that were indeterminate. GeneXpert results were interpreted by an independent observer without the knowledge of results of reference standard.
Sequencing
The genomic bacterial DNA of culture isolates was obtained by heat lysis method [17] and amplified using standardized protocols. The 81-bp rpoB hot-spot region [RRDR]]region was amplified by PCR and DNA sequencing done with specific primers. For mutation analysis of the RRDR, a 437-bp fragment of the rpoB gene was amplified using primers rpoB-for 5´TGGTCCGCTTGCACGAGGGTCAGA-3´and rpoB-rev 5´-CTCAGGGGTTTCGATCGGGCACAT-3´as described previously [18] . 
Definitions
The patients were followed for two years following the diagnosis and institution of treatment. Adequate response to treatment was assessed in terms of improvement in signs and symptoms such as fever, lymphadenopathy, fluid collection, improvement in general well-being, and weight gain. The CRS for biopsy samples and aspirates included parameters such as culture, histology and cytology, radiology and response to treatment during follow-up visits. 
Study definitions
A case of pulmonary TB is considered to be smear-positive if one or more sputum smear specimens at the start of treatment are positive for AFB. New sputum smear-positive pulmonary TB case is the presence of at least one acid-fast bacillus [AFB+] in at least one sputum sample and a case of pulmonary TB is considered to be smear-negative if at least two sputum specimens at the start of treatment are negative for AFB in countries with a functional EQA system. [19] Reference standard comparison
The Xpert results from all the pulmonary and extra-pulmonary samples were compared with CRS as shown in Table 1 . For pulmonary TB, diagnosis was given if any two of smear/culture/ response to treatment/radiological findings were positive and for EPTB, diagnosis was given if any two of smear/culture/histopathology/cytology/biochemical analysis/ response to treatment/ADA levels/radiological findings were positive [ Table 1 ]. Response to treatment was recorded at 6 months and again at 2 years follow-up.
Culture [including Liquid Culture [LC] ] is an accepted gold standard. [20] Nevertheless, in pauci-bacillary disease such as EPTB, the culture yield may be poor, while the molecular tests have the ability to detect DNA from non-viable organisms with a LOD ranging between 5 to 100 bacilli/ml, hence may detect culture negative samples. CRS has been used as gold standard in studies to overcome such issues, though it may suffer from poor specificity. [21] Hence, both culture and CRS were used as reference standards in order to reach an optimum sensitivity and specificity [ Table 1 ]. In addition sequencing was used to identify the mutations for comparison with GeneXpert results [ Table 2 ]. 
Statistical analysis
The sample size was calculated prior to the initiation of the study. The sample size was established using the Statistical formula:
Where P = prevalence and d = precision, using the test sensitivity as 80% and specificity 98% [3] . P is pre-determined value of sensitivity [or specificity] that is ascertained by previous published data or clinician experience/judgment. A sample size of 693 was suggested for EPTB including controls.
Sensitivity and specificity, of the GeneXpert MTB/RIF, respective 95% confidence intervals [95% CI] were calculated after comparison to the results of the phenotypic gold standard MGIT 960, [liquid culture drug susceptibility testing LC-DST] and CRS.
Kappa chi square test was performed for the agreement analysis. A p-value of 0.05 was considered as statistically significant. All data were analyzed using STATA statistical software version 12.1 [StataCorp LP, College Station, TX, USA].
Forest plot
Forest plot was drawn in order to draw comparison with available published literature on the use of GeneXpert in EPTB. For each published study, we calculated GeneXpert MTB/RIF sensitivity and specificity along with 95% confidence intervals, compared with CRS, and generated forest plots to display sensitivity and specificity estimates using STATA statistical software version 11. The sensitivity and specificity varied across the samples. The square boxes indicate the size of the study. The dotted line is a visual assessment of the heterogeneity of the studies. Confidence Intervals are a measure of the precision of the results of a study. 
Results

Characteristics of the study population
Patients enrolled for the study were in the male: female ratio of 
Performance of GeneXpert for the diagnosis of TB
In pulmonary group GeneXpert detected TB in 72 culture positive and 114 culture negative patients, while in extra-pulmonary group it detected TB in 35 culture positive and 181 culture negative patients, thus aiding treatment decisions in 295 patients in whom culture was negative.
Comparison of results with composite reference standards
An interesting finding [ Table 1 ] was a group of patients who were GeneXpert test positive but for whom a delayed/ no response to treatment was recorded at 6 months. Forty-one of 48 such patients with EPTB were resistant to Rifampicin by GeneXpert and were given treatment for MDR-TB, while four had gastrointestinal TB, and three had CNS-TB. Two-year follow-up showed response to treatment in all the 48 MDR-TB patients except two with CNS-TB.
Indeterminate results
Four samples [ 
Performance of GeneXpert for detection of Rif resistance
Of the culture positive samples, the Xpert MTB/RIF assay detected Rif resistance in 14/72 pulmonary samples and 9/35 extra-pulmonary samples. The C T values for different probes for the Rif resistant samples are plotted in Fig 2. Twenty-three samples were correctly identified as Rif resistant. Twenty-one of 23 Rif resistant samples had at least one negative probe, while two samples were detected as resistant as the ΔCt was more than 4 between any 2 probes.
Comparison of GeneXpert assay results with phenotypic and genotypic gold standards
Seventy-two pulmonary and 35 extra-pulmonary samples were culture positive. These were further subjected to DST on MGIT 960 [LC-DST] and PCR-sequencing. The results on LC-DST were compared to the Xpert MTB/RIF assay [ Table 2 ] The DST results were discordant with the Xpert results in 2/72 pulmonary samples and 2/35 extra-pulmonary samples. In all the four cases the Xpert showed the sample as sensitive while the culture isolates were resistant [0.5ug/ml and 1ug/ml Rifampicin] [ Table 3 ]. Further, using sequencing as gold standard, the Rif resistance mutations were detected in 25/27 samples resistant to Rif by LC-DST [ Table 2 ]. One pulmonary and one extra-pulmonary sample had been incorrectly missed by the Xpert assay [ Table 2 ]. In addition, two samples missed by Xpert assay but resistant by LC-DST did not show any mutation in the RRDR region sequenced. The resistance in these two cases may be ascribed to other mechanisms such as efflux-pumps or mutations outside of RRDR. One isolate from sputum sample was sensitive to Rif by LC-DST, sensitive by Xpert but showed two mutations on sequencing, CGA529CGG, CTG530CTT.These mutations have not been reported or associated with drug resistance before, and may possibly be silent mutations.
Bacillary load and drug resistance
Quantitation of bacillary load by Xpert assay is determined by threshold-cycle [Ct]; High Ct value is <16; Medium Ct value is16-22; Low Ct value is 22-28; Very Low Ct value is >28. The higher bacillary load, when plotted against Rif and INH resistance profiles showed a statistically significant association with drug resistance [ Table 4 ].
Mutations identified by sequencing, missed by Xpert assay
The G4 cartridges have been improvised to address the detection of mutation at 533 CCG. Nevertheless, one culture with the 533 CCG mutation was missed in the study [Δ Ct was 3.1 between 2 probes, system is capable of detecting >4]. In addition the Xpert assay missed the mutations CAG517AAG, AAC519CAC in one isolate from pus sample detected resistant in Statistically significant association was found between the bacillary load as detected by GeneXpert system in pulmonary samples [p<0.001] and drug resistance both to Rif and INH, detected using LC-DST, however most of the extra-pulmonary samples were pauci-bacillary to draw any correct inference. 
LC-DST [Δ
Discussion
The Xpert assay has brought about a major change in the speed, simplicity and accuracy of not only diagnosis of TB but also drug resistance to RIF in TB, which is accepted as a surrogate for MDR-TB. The sensitivity of detection enables diagnosis in smear negative and often culture negative TB. The rapidity and robustness of diagnosis in-turn breaks the chain of transmission in addition to early institution of treatment and improved chances for cure. The utility of Xpert assay in diagnosis of pauci-bacillary TB is the most important contribution of the test. WHO policy document 2013 adopted a GRADE system approach to arrive at recommendations [9] on the diagnostic value of the assay in Pulmonary and EPTB. RIF resistance detection in the Xpert assay is based on hybridization [or the absence] of five molecular beacon probes complementary to the wild type sequence of rpoB gene [responsible for 95% of drug resistance mutations in the RRDR, codons 507 to 533]. The inherent nature of the technique being highly dependent on a strict ionic milieu and inter-molecular forces, may sometimes subject the fidelity to question. Blakemore et al 2012 [4] suggest that the detection of mutations in RRDR varies with the nature of the mutations; the mutations capable of completely inhibiting the binding of molecular beacons are easier to detect than the ones causing a delay. Most of the Rif resistance mutations are of the first kind hence are easily detected [2] .
The use of wild type probes ensures the detection of rarely reported or unreported mutations as well. Some of the rpoB mutations have been reported to be associated with Rif susceptible genotypes [22] [23] [24] [25] [26] [27] [28] . The data on these issues are contradictory. The detection of only the RRDR mutations misses the resistance determining mutations outside the hotspot, such as 572Phe and a few others, together responsible for upto 5% of all Rif mutations [28] , possibly responsible for two isolates in our study.
In the present study, Xpert detected four samples discordant with culture DST. On sequencing, two showed mutations [517,519 [dual mutation] and 533CCG], while two others had no mutation in the RRDR. Kim et al 2012 suggested that the mutations at probe ends might be missed [29] . In their study a Δ Ct of 3.2 was responsible for the failure of detection of 518Asp mutation by Probe C as it was lying at the probe end. The missed dual mutations in the present study, 517, 519 and 529,530 are at the junction of Probes B & C, and D & E, and may have been missed due to competition for binding.
The detection of 533Pro has long been a subject of debate till the time the G3 cartridges were in use; with the new G4 cartridges the error rate was expected to be low [23] . For detection by Xpert, 100% mutant DNA with 533 CCG mutation is required, while in case of 531 CTG mutations, 65% mutant DNA is adequate for detection [4] .
Mixed MTB infections have been suggested to be responsible for false negative and positive results for RIF by Xpert [30] . Hetero-resistance defined as the presence of both sensitive and resistantMTB populations is often suggested to be responsible for discordant DST results [23] . Several studies have shown that mixed populations do not usually occur [2, [31] [32] , however reports of mixed infections warrant further studies to evaluate its interference with drug resistance detection [33, 34] . For the same reason, Xpert cannot be used for assessing the emergence of Rif resistance during treatment [4] .
Line Probe Assay [LPA] is said to be capable of indicating hetero-resistance but the LOD of LPA is at least 5X10 3 bacilli per ml of sample, hence the bacillary load in the mixed population would need to be high enough for detection using reverse hybridization by LPA. The LPA also may not detect all mutations at position 533; the probes are so designed that the mutation does not always affect the loss of binding of probes [35, 36] . Chakravorty et al 2012 used 'sloppy molecular beacons' to enable detection of 40% mutant DNA in samples, equivalent to that detected by sequencing [37] .The study demonstrated statistically significant correlation between Rif and INH resistance and the bacterial load as determined by the Ct value. This seconds the findings by several researchers who have demonstrated increased chances of drug resistance in higher bacillary loads. Higher bacillary load has been shown to predispose to accumulation of resistance mutations due to higher number of replication cycles and hence higher chances of occurrence and accumulation of such mutations [38] . [24] . Possible inclusion of specific mutant probes in the GeneXpert test design could assist treatment decisions. The frequency of 533Pro mutation responsible for LLR has been reported globally to range from 3% to 6% [39] and hence may not be as salient as the other more frequent HLR mutations.
In the present study, GeneXpert assay was extremely useful in establishing an early diagnosis in several pulmonary and extra-pulmonary samples, in which the smears as well as culture failed to give any clue to diagnosis. The use of CRS offered a good comparison for GeneXpert. Few patients with EPTB, who had been diagnosed as resistant to Rif showed a delayed response, though on MDR-TB treatment. Response to treatment at such extra-pulmonary sites may take longer to appear. Two-year follow-up in these patients showed resolution of symptoms in most patients.
Forest plot in Fig 3 compares the sensitivity and specificity for diagnosis of TB by GeneXpert in the present study with published work. The sensitivity for TB detection in CSF samples was similar to the study by Vadwai et al. while it was better than other studies in pleural fluid samples and lymph node aspirates. Specificity of TB detection was comparable to other studies for CSF samples, but slightly lower for other samples. Variations in different studies suggest optimization of sample processing protocols for foolproof amplification results. [Part of the study data contributed to the WHO policy document 2013, [obscured, awaiting publication] [8] .
Van Deun et al 2013 and Jamieson et al 2014 have shown that cultures with certain 'disputed' drug resistance mutations [511Pro, 516Tyr, 526Asn, 526Leu, 533Pro, and 572Phe] may be slow to grow in the presence of drug [fitness loss] and hence may be labeled as sensitive and would be ideally identified from the sample directly [24, 28] In our series both MGIT and Xpert detected all so-called 'disputed' mutations except one 533CCG mutation. However several studies have demonstrated the need to revise the critical concentrations used in MGIT-DST [Phenotypic gold standard] from 1ug/ml to 0.5ug/ml or even lower [24, 28, 40, 41] .
The relevance of all the tests and efforts at resistance detection should translate into clinical care, predict the drugs useful and those not useful. Rif is the mainstay of TB treatment, removal of Rif from treatment protocol is a major decision. Phenotypic DST based on culture, though slow, detects all clinically relevant resistance and clearly serves as the gold standard for drug resistance diagnosis. Including one extra tube with 0.5ug/ml Rif can easily incorporate the detection of mutations responsible for low-level resistance to Rif. The drug levels achievable with 600 mg dosage of Rif is 1.5ug/ml of free drug, which is capable of inactivating strains with MIC up to 0.375ug/ml. Therapeutic drug monitoring can further assist treatment design.
Genotypic assays though offer rapidity and most often a good sensitivity when the probes designed can cover all possible mutations responsible for resistance but could give false positive results due to detection of mutations not responsible for resistance. Also the current methods cannot detect the level of drug resistance, hence cannot be used for deciding in favor of Rifabutin as an alternative drug of choice. The current design of the Xpert assay would miss the resistance detection in mixed samples and Rif resistance outside RRDR. Bacterial load in the samples may have a bearing on the resistance detection; hence repeat sampling may not always resolve the issue of resistance in low load samples. Nevertheless Xpert is the best bet today that offers rapid detection of Rif resistance with reasonable precision. It is rightly recommended to be the "Initial Diagnostic test", aided by conventional microscopy and culture for monitoring therapy and DST for INH and second-line drugs especially in Rif resistant cases.
